Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Chlorothiazide
Drug ID BADD_D00442
Description A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
Indications and Usage Chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
Marketing Status approved; vet_approved
ATC Code C03AA04
DrugBank ID DB00880
KEGG ID D00519
MeSH ID D002740
PubChem ID 2720
TTD Drug ID D0M9WM
NDC Product Code 42419-007; 12828-0005; 38779-3147; 33656-0012; 65649-311; 59605-1745; 57821-001
UNII 77W477J15H
Synonyms Chlorothiazide
Chemical Information
Molecular Formula C7H6ClN3O4S2
CAS Registry Number 58-94-6
SMILES C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nausea07.01.07.001--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pancreatitis07.18.01.001--
Paraesthesia23.03.03.094; 17.02.06.005--
Photosensitivity reaction23.03.09.003--
Pneumonia11.01.09.003; 22.07.01.003--Not Available
Pneumonitis22.01.01.006--
Pulmonary oedema02.05.02.003; 22.01.03.003--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Respiratory distress22.02.01.012--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Sialoadenitis11.01.04.002; 07.06.04.002--
Stevens-Johnson syndrome12.03.01.014; 11.07.01.005; 10.01.01.045; 23.03.01.007--
Thrombocytopenia01.08.01.002--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Urticaria23.04.02.001; 10.01.06.001--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vasculitis24.12.04.027; 10.02.02.006--
Vasculitis necrotising24.12.04.029; 10.02.02.008--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Xanthopsia06.02.05.002--Not Available
Tubulointerstitial nephritis20.05.02.002--Not Available
Epigastric discomfort07.01.02.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages